Moreover, interruption or discontinuation of SGLT-2 inhibitor as a result of UTI was rare (0.2–0.3% of patients treated with dapagliflozin compared with 0.1% in the placebo group [35]. Here, SLC5A2 is linked to bacterial urinary tract infection.